Form 4: Stoke Therapeutics' General Counsel Jonathan Allan Reports Stock Sale

Jonathan Allan, General Counsel of Stoke Therapeutics, reports the sale of 8,599 shares of common stock on May 20, 2024, according to a Form 4 filing.

Summary

• On May 20, 2024, Jonathan Allan, the General Counsel of Stoke Therapeutics, executed a transaction involving the company's common stock.
• Allan sold 8,599 shares at a weighted average price of $15.0398 per share, with individual prices ranging from $15.00 to $15.16.
• This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023.
• Additionally, Allan exercised a stock option to acquire 8,599 shares at a price of $7.07 per share.
• Following these transactions, Allan directly owns 2,598 shares of Stoke Therapeutics common stock and 25,801 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions by an insider under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Comparing Jonathan Allan's transactions to those of other General Counsels in similarly sized biotech companies would provide a benchmark.
• Analyzing the frequency and size of insider sales at companies like Wave Life Sciences or Sarepta Therapeutics could offer context.
• The use of a 10b5-1 trading plan is a standard practice, and its presence here aligns with industry norms for managing insider trading risks.

Key Dates